Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan C Fox

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
European Heart Journal|July 15, 2015
SHaRe: advancing the goal of effective treatment for cardiomyopathyJonathan C Fox
Expert Opinion on Pharmacotherapy|May 25, 2004
Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY ProgrammeHerbert Schuster, Jonathan C Fox
Lancet (London, England)|March 20, 2004
Rosuvastatin-warfarin drug interactionGunnar O Olsson, Jonathan C Fox
The New England Journal of Medicine|April 10, 2024
Acoramidis in Transthyretin Amyloid Cardiomyopathy. ReplyJulian D Gillmore, Ted Lystig, Jonathan C Fox
Journal of Neuropathology and Experimental Neurology|November 15, 2002
Autocrine signaling through Ras regulates cell survival activity in human glioma cells: potential cross-talk between Ras and the phosphatidylinositol 3-kinase-Akt pathwayKiyohiko Sakata, Seiya Kato, Jonathan C Fox, et al.
Atherosclerosis|January 16, 2007
Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemiaYasushi Saito, Nobuhiro Yamada, Kohji Shirai, et al.
International Journal of Oncology|August 9, 2002
Inhibition of autocrine fibroblast growth factor signaling by the adenovirus-mediated expression of an antisense transgene or a dominant negative receptor in human glioma cells in vitroTakachika Aoki, Seiya Kato, Jonathan C Fox, et al.
American Journal of Physiology. Heart and Circulatory Physiology|December 4, 2012
AMP-activated protein kinase inhibits vascular smooth muscle cell proliferation and migration and vascular remodeling following injuryJoshua D Stone, Avinash Narine, Patti R Shaver, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 10, 2011
The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathwaysChintamani N Joshi, Danielle N Martin, Jonathan C Fox, et al.
Clinical Pharmacology in Drug Development|June 8, 2019
First-in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult VolunteersJonathan C Fox, Jennifer L Hellawell, Satish Rao, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
European Heart Journal|July 15, 2015
SHaRe: advancing the goal of effective treatment for cardiomyopathyJonathan C Fox
Expert Opinion on Pharmacotherapy|May 25, 2004
Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY ProgrammeHerbert Schuster, Jonathan C Fox
Lancet (London, England)|March 20, 2004
Rosuvastatin-warfarin drug interactionGunnar O Olsson, Jonathan C Fox
The New England Journal of Medicine|April 10, 2024
Acoramidis in Transthyretin Amyloid Cardiomyopathy. ReplyJulian D Gillmore, Ted Lystig, Jonathan C Fox
Journal of Neuropathology and Experimental Neurology|November 15, 2002
Autocrine signaling through Ras regulates cell survival activity in human glioma cells: potential cross-talk between Ras and the phosphatidylinositol 3-kinase-Akt pathwayKiyohiko Sakata, Seiya Kato, Jonathan C Fox, et al.
Atherosclerosis|January 16, 2007
Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemiaYasushi Saito, Nobuhiro Yamada, Kohji Shirai, et al.
International Journal of Oncology|August 9, 2002
Inhibition of autocrine fibroblast growth factor signaling by the adenovirus-mediated expression of an antisense transgene or a dominant negative receptor in human glioma cells in vitroTakachika Aoki, Seiya Kato, Jonathan C Fox, et al.
American Journal of Physiology. Heart and Circulatory Physiology|December 4, 2012
AMP-activated protein kinase inhibits vascular smooth muscle cell proliferation and migration and vascular remodeling following injuryJoshua D Stone, Avinash Narine, Patti R Shaver, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 10, 2011
The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathwaysChintamani N Joshi, Danielle N Martin, Jonathan C Fox, et al.
Clinical Pharmacology in Drug Development|June 8, 2019
First-in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult VolunteersJonathan C Fox, Jennifer L Hellawell, Satish Rao, et al.
Pageof 4